On July 24, GPC Biotech will go before the Oncologic Drugs Advisory Committee (ODAC) for a crucial review of its investigational prostate drug, satraplatin.
As companies in the sector become more involved in regulatory proceedings, they are discovering that a well-planned communications strategy can go a long way.
It's a big day for Laurie Doyle, GPC's director of IR and corporate communications, and her team, who have long been preparing for that day with the assistance of Russo Partners.
Satraplatin is a ...